Cargando…

Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study

BACKGROUND: Short-term infusions of dinutuximab beta plus isotretinoin and cytokines administered in previous immunotherapy studies in neuroblastoma were associated with severe pain. Here, long-term, continuous infusion of single-agent dinutuximab beta was evaluated in patients with relapsed/refract...

Descripción completa

Detalles Bibliográficos
Autores principales: Lode, Holger N., Ehlert, Karoline, Huber, Stephanie, Troschke-Meurer, Sascha, Siebert, Nikolai, Zumpe, Maxi, Loibner, Hans, Ladenstein, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667538/
https://www.ncbi.nlm.nih.gov/pubmed/37813959
http://dx.doi.org/10.1038/s41416-023-02457-x
_version_ 1785139272283586560
author Lode, Holger N.
Ehlert, Karoline
Huber, Stephanie
Troschke-Meurer, Sascha
Siebert, Nikolai
Zumpe, Maxi
Loibner, Hans
Ladenstein, Ruth
author_facet Lode, Holger N.
Ehlert, Karoline
Huber, Stephanie
Troschke-Meurer, Sascha
Siebert, Nikolai
Zumpe, Maxi
Loibner, Hans
Ladenstein, Ruth
author_sort Lode, Holger N.
collection PubMed
description BACKGROUND: Short-term infusions of dinutuximab beta plus isotretinoin and cytokines administered in previous immunotherapy studies in neuroblastoma were associated with severe pain. Here, long-term, continuous infusion of single-agent dinutuximab beta was evaluated in patients with relapsed/refractory neuroblastoma. METHODS: In this open-label, single-arm, Phase 2 study, patients with either refractory or relapsed high-risk neuroblastoma received dinutuximab beta by continuous infusion over 10 days of each cycle, for up to five cycles. The primary endpoint was objective response rate 24 weeks after the end of cycle 5. Secondary endpoints included adverse events, intravenous morphine use, best response, duration of response, and three-year progression-free and overall survival. RESULTS: Of the 40 patients included, 38 had evaluable response. Objective response rate was 26% and best response rate 37%. Median duration of response was 238 days (IQR 108–290). Three-year progression-free and overall survival rates were 31% (95% CI 17–47) and 66% (95% CI 47–79), respectively. Prophylactic intravenous morphine use and duration of use decreased with increasing cycles. The most common grade 3 treatment-related adverse events were pain, diarrhea, and hypokalemia. CONCLUSION: Long-term continuous infusion of single-agent dinutuximab beta is tolerable and associated with clinically meaningful responses in patients with relapsed/refractory high-risk neuroblastoma. CLINICAL TRIAL REGISTRATION: The study is registered with ClinicalTrials.gov (NCT02743429) and EudraCT (2014-000588-42).
format Online
Article
Text
id pubmed-10667538
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-106675382023-10-10 Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study Lode, Holger N. Ehlert, Karoline Huber, Stephanie Troschke-Meurer, Sascha Siebert, Nikolai Zumpe, Maxi Loibner, Hans Ladenstein, Ruth Br J Cancer Article BACKGROUND: Short-term infusions of dinutuximab beta plus isotretinoin and cytokines administered in previous immunotherapy studies in neuroblastoma were associated with severe pain. Here, long-term, continuous infusion of single-agent dinutuximab beta was evaluated in patients with relapsed/refractory neuroblastoma. METHODS: In this open-label, single-arm, Phase 2 study, patients with either refractory or relapsed high-risk neuroblastoma received dinutuximab beta by continuous infusion over 10 days of each cycle, for up to five cycles. The primary endpoint was objective response rate 24 weeks after the end of cycle 5. Secondary endpoints included adverse events, intravenous morphine use, best response, duration of response, and three-year progression-free and overall survival. RESULTS: Of the 40 patients included, 38 had evaluable response. Objective response rate was 26% and best response rate 37%. Median duration of response was 238 days (IQR 108–290). Three-year progression-free and overall survival rates were 31% (95% CI 17–47) and 66% (95% CI 47–79), respectively. Prophylactic intravenous morphine use and duration of use decreased with increasing cycles. The most common grade 3 treatment-related adverse events were pain, diarrhea, and hypokalemia. CONCLUSION: Long-term continuous infusion of single-agent dinutuximab beta is tolerable and associated with clinically meaningful responses in patients with relapsed/refractory high-risk neuroblastoma. CLINICAL TRIAL REGISTRATION: The study is registered with ClinicalTrials.gov (NCT02743429) and EudraCT (2014-000588-42). Nature Publishing Group UK 2023-10-10 2023-11-23 /pmc/articles/PMC10667538/ /pubmed/37813959 http://dx.doi.org/10.1038/s41416-023-02457-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Lode, Holger N.
Ehlert, Karoline
Huber, Stephanie
Troschke-Meurer, Sascha
Siebert, Nikolai
Zumpe, Maxi
Loibner, Hans
Ladenstein, Ruth
Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study
title Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study
title_full Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study
title_fullStr Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study
title_full_unstemmed Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study
title_short Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study
title_sort long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, phase 2 study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667538/
https://www.ncbi.nlm.nih.gov/pubmed/37813959
http://dx.doi.org/10.1038/s41416-023-02457-x
work_keys_str_mv AT lodeholgern longtermcontinuousinfusionofsingleagentdinutuximabbetaforrelapsedrefractoryneuroblastomaanopenlabelsinglearmphase2study
AT ehlertkaroline longtermcontinuousinfusionofsingleagentdinutuximabbetaforrelapsedrefractoryneuroblastomaanopenlabelsinglearmphase2study
AT huberstephanie longtermcontinuousinfusionofsingleagentdinutuximabbetaforrelapsedrefractoryneuroblastomaanopenlabelsinglearmphase2study
AT troschkemeurersascha longtermcontinuousinfusionofsingleagentdinutuximabbetaforrelapsedrefractoryneuroblastomaanopenlabelsinglearmphase2study
AT siebertnikolai longtermcontinuousinfusionofsingleagentdinutuximabbetaforrelapsedrefractoryneuroblastomaanopenlabelsinglearmphase2study
AT zumpemaxi longtermcontinuousinfusionofsingleagentdinutuximabbetaforrelapsedrefractoryneuroblastomaanopenlabelsinglearmphase2study
AT loibnerhans longtermcontinuousinfusionofsingleagentdinutuximabbetaforrelapsedrefractoryneuroblastomaanopenlabelsinglearmphase2study
AT ladensteinruth longtermcontinuousinfusionofsingleagentdinutuximabbetaforrelapsedrefractoryneuroblastomaanopenlabelsinglearmphase2study